Biocon’s insulin biosimilar rejected yet again by FDA after manufacturing deficienciesnews2023-10-09T16:58:28+00:00October 9th, 2023|Endpoints News|
Hamas strikes could impact some biopharma operations in Israelnews2023-10-09T15:37:15+00:00October 9th, 2023|Endpoints News|
Scoop: Novartis axes mid-stage depression trial of ketamine-like injectionnews2023-10-09T15:31:33+00:00October 9th, 2023|Endpoints News|
Return of the megaround: Main Street Health raises $315M for value-based carenews2023-10-09T15:21:01+00:00October 9th, 2023|Endpoints News|
BridgeBio’s long-term limb-girdle muscular dystrophy data; QHP buys a CDMOnews2023-10-09T14:55:14+00:00October 9th, 2023|Endpoints News|
Uber and Instacart expand their health plan partnershipsnews2023-10-09T14:54:38+00:00October 9th, 2023|Endpoints News|
Why the CEO at Northwell Health bets it can create the future of healthcare rather than respond to it: #HLTH23news2023-10-09T14:25:06+00:00October 9th, 2023|Endpoints News|
Vertex CSO David Altshuler on AI in biotech, pain pills and scientific breakthroughsnews2023-10-09T13:00:49+00:00October 9th, 2023|Endpoints News|
FDA rejects Alnylam’s Onpattro label expansion after adcomm voted in favornews2023-10-09T11:48:51+00:00October 9th, 2023|Endpoints News|
Novartis, Bristol Myers back $61M Series A raise for dementia biotech AstronauTxnews2023-10-09T10:47:07+00:00October 9th, 2023|Endpoints News|
